These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
704 related articles for article (PubMed ID: 30877063)
21. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update. Roskoski R Pharmacol Res; 2024 Feb; 200():107059. PubMed ID: 38216005 [TBL] [Abstract][Full Text] [Related]
22. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Roskoski R Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593 [TBL] [Abstract][Full Text] [Related]
23. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders. Roskoski R Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738 [TBL] [Abstract][Full Text] [Related]
24. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers. Roskoski R Pharmacol Res; 2017 Mar; 117():343-356. PubMed ID: 28077299 [TBL] [Abstract][Full Text] [Related]
25. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Roskoski R Pharmacol Res; 2015 Apr; 94():9-25. PubMed ID: 25662515 [TBL] [Abstract][Full Text] [Related]
26. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders. Roskoski R Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617 [TBL] [Abstract][Full Text] [Related]
27. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers. Roskoski R; Sadeghi-Nejad A Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153 [TBL] [Abstract][Full Text] [Related]
28. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. Roskoski R Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305 [TBL] [Abstract][Full Text] [Related]
29. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. Roskoski R Pharmacol Res; 2017 Mar; 117():20-31. PubMed ID: 27956260 [TBL] [Abstract][Full Text] [Related]
30. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. Roskoski R Pharmacol Res; 2014 Sep; 87():42-59. PubMed ID: 24928736 [TBL] [Abstract][Full Text] [Related]
31. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas. Roskoski R Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784 [TBL] [Abstract][Full Text] [Related]
32. Protein kinase inhibitors: contributions from structure to clinical compounds. Johnson LN Q Rev Biophys; 2009 Feb; 42(1):1-40. PubMed ID: 19296866 [TBL] [Abstract][Full Text] [Related]
33. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. Roskoski R Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677 [TBL] [Abstract][Full Text] [Related]
34. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. Roskoski R Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216 [TBL] [Abstract][Full Text] [Related]
35. Sunitinib, sorafenib and mTOR inhibitors in renal cancer. Radulovic S; Bjelogrlic SK J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273 [TBL] [Abstract][Full Text] [Related]